Premium
Real‐world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end‐of‐treatment response
Author(s) -
Williams James,
Lucarelli Nicolas,
Nicoll Amanda,
Lubel John
Publication year - 2019
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14279
Subject(s) - medicine , antiviral therapy , cirrhosis , hepatitis c , hepatitis c virus , gastroenterology , immunology , chronic hepatitis , virus
There are limited real‐world data on the efficacy of direct acting antiviral (DAA) therapy for hepatitis C (HCV) in Australia. In this study, the efficacy of DAA therapy for HCV was compared between cirrhotic and non‐cirrhotic cohorts. Patients without end‐of‐treatment response (EoTR) were observed to ascertain likelihood of achieving sustained virological response at 12 weeks post‐treatment (SVR12). A total of 334 patients with HCV was included. Overall SVR12 was 96.7% with minimal differences in SVR12 between the cirrhosis and non‐cirrhosis groups (95.7 and 97.3%). There were 20 patients (5.99%) that failed to achieve an EoTR of which 80.0% ( n = 16) went on to achieve SVR12. These results suggest DAA therapy is effective with high rates of SVR12 even in patients that do not achieve an EoTR.